A Better Newspaper

## Overview Helical Ltd. announced a **$10 million funding round** to expand its virtual AI lab platform, which converts biological foundation models into reproducible in-silico drug discovery workflows (SiliconAngle, April 14). Founded in 2024, Helical was built around a gap its founders identified as biological foundation models gained traction but struggled to translate into actionable pharmaceutical decisions. ## Platform Description Helical's platform reportedly turns biological foundation models into reproducible **in-silico drug discovery workflows** (SiliconAngle, April 14). The emphasis on reproducibility addresses a known credibility problem in AI-assisted drug discovery: many AI-generated biological predictions have proven difficult to replicate or translate into experimental validation. By building standardized workflows around foundation models, Helical is positioning itself as infrastructure for pharmaceutical R&D teams rather than a model developer. ## Market Context The pharma AI sector has seen significant investment in foundation model development (e.g., AlphaFold, ESM, and various genomics models), but the translation layer between model outputs and drug development decisions remains underdeveloped. Helical's approach of focusing on this workflow translation gap is consistent with a maturing market where infrastructure and tooling attract capital alongside raw model development. ## Competitive Landscape Helical competes in a space that includes Recursion Pharmaceuticals, Insilico Medicine, and a range of AI-native biotech startups, as well as the internal AI teams of major pharmaceutical companies. Its differentiation reportedly lies in reproducibility and workflow standardization rather than model novelty. ## Considerations for Attorneys & Entrepreneurs - **Regulatory pathway**: FDA and EMA are developing frameworks for AI-assisted drug discovery submissions; reproducibility requirements may become a regulatory prerequisite, advantaging Helical's positioning. - **IP**: Workflows built on third-party foundation models create complex ownership questions around derivative outputs. - **Validation liability**: If Helical's workflows inform clinical decisions that result in adverse outcomes, liability allocation between platform, model provider, and pharmaceutical company will be contested.